(Q73028987)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

A M Wilson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

B J Lipworth

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 March 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

269-275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

Measurement of airway hyperresponsiveness: new considerations

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Measuring exhaled nitric oxide: not only a matter of how--but also why--should we do it?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Serum eosinophil cationic protein (ECP) in chronic asthma. Relationship to spirometry, flow-volume curves, PC20, and exacerbations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Relationship between activated eosinophils of the bronchial mucosa and serum eosinophil cationic protein in atopic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Bioequivalent doses of budesonide and prednisone in moderate and severe asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Dosage and time effects of inhaled budesonide on bronchial hyperreactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Effect of measurement conditions on measured levels of peak exhaled nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs☆☆☆★★★

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Budesonide treatment of moderate and severe asthma in children: a dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Physiologic consequences of long-term inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

An inhaled steroid improves markers of airway inflammation in patients with mild asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Effect of Early vs Late Intervention With Inhaled Corticosteroids in Asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Greater effect of inhaled budesonide on adenosine 5'-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

Effects of airway calibre on lung delivery of nebulised salbutamol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900435-0

10.1016/S0002-9343(99)00435-0

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11014718%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference